Stratpharma

What Stratpharma does

Stratpharma AG is a Swiss specialty medical device company founded in 2005 and headquartered in Basel. It develops, manufactures, and markets a portfolio of eight topical film-forming silicone gel products for dermatology, wound care, scar management, oncology supportive care, women's health, and post-procedure skin recovery. The core platform technology produces gas-permeable, waterproof, self-drying silicone barrier gels that are sold as registered medical devices, each tailored to a specific clinical indication: Strataderm (scars), Stratamed (wound healing), Stratacel (post-resurfacing), Stratamark (stretch marks), StrataXRT (radiation dermatitis), StrataCTX (dry skin and cutaneous rashes), StrataMGT (vaginal atrophy and lichenoid dermatoses), and Colsigen (Type III Collagen skincare). Products are classified as medical devices, with some acting as U.S. prescription items, supported by ISO 13485 manufacturing certification, FDA registration, and broader international clearances.

The company's revenue model relies on one-time product sales of registered medical devices, distributed globally through pharmaceutical distribution partners and, in select markets, directly. It operates a hybrid go-to-market combining channel partner networks for broad geographic reach with wholly-owned subsidiaries in the U.S., Australia, Ireland, Spain, Romania, Greece, Japan, and China, plus a direct e-commerce storefront. Marketing is driven through peer-reviewed clinical evidence and participation in major medical congresses (ESTRO, ONS, SCALE, AAD) targeting dermatology, oncology, plastic surgery, wound care, and aesthetic medicine channels. Customer segments span oncology patients undergoing radiation/chemotherapy/immunotherapy, patients with hypertrophic scars or keloids, women's health patients, post-aesthetic procedure patients, and acute/chronic wound cases, addressed through healthcare professionals, key opinion leaders, and direct-to-consumer routes.

Name

Stratpharma

Legal name

Stratpharma AG

Website

https://stratpharma.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Stratpharma AG is a Basel-based medical device company developing and marketing eight topical silicone gel products for scar management, wound care, oncology supportive care, women's health, and post-aesthetic skin recovery, distributed in over 70 countries.

Ownership category

akta.pro rank

Product category

Topical Medical Devices for Dermatology

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Topical medical devices
• Dermatology wound care
• Scar management products
• Oncology supportive care
• Women's health devices

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Product Sales: Stratpharma develops, manufactures and markets topical medical device products (silicone gels, wound dressings) for dermatology, wound care, scar management, women's health, and oncology supportive care. Revenue generated through product sales via distribution partners globally and direct marketing in select markets like Australia.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Stratpharma AG designs, develops, manufactures, and markets a portfolio of eight topical medical devices based on proprietary film-forming silicone gel technology for dermatology, scar management, wound care, oncology supportive care, and women's health. The products are sold as registered medical devices in 80+ countries with marketing authorization, distributed globally through pharmaceutical partners and direct subsidiaries.

Product overview

Stratpharma is a Swiss-based company that develops and commercializes innovative topical medical devices across Dermatology, Plastic Surgery, Burn Care, Radiation and Oncology Supportive Care, Women's Health, and Wound and Scar Management. The portfolio consists of eight distinct film-forming gel products: Strataderm (scar therapy), Stratamed (wound healing), Stratacel (post-procedure care), Stratamark (stretch mark prevention/treatment), StrataXRT (radiation dermatitis), StrataCTX (dry skin/rashes), StrataMGT (vaginal conditions), and Colsigen (Type III Collagen skincare). All products are classified as medical devices and use advanced film-forming silicone gel technology to create protective, gas-permeable, waterproof barriers that support healing and symptom management.

Differentiator

Problem solved

Functional benefit

Brands

• Strataderm: Rapidly drying, non-sticky, transparent silicone gel formulation for prevention and treatment of scars, hypertrophic scars and keloids.
• Stratamed
• Stratacel
• Stratamark
• StrataXRT
• StrataCTX
• StrataMGT
• Colsigen

Products and services

• Strataderm Rapidly drying, non-sticky, transparent silicone gel formulation for the prevention and treatment of old and new scars, hypertrophic scars, and keloids; dries to form a protective layer that is gas-permeable and waterproof, hydrating, softening, and protecting scars. Targeted at healthcare professionals and patients requiring professional scar therapy.
• Stratamed Advanced flexible, film-forming wound dressing for use immediately following medical and aesthetic procedures, on acute or chronic wounds, and compromised skin surfaces; developed with special consistency to ensure full contact with the wound bed. For healthcare providers and patients in post-procedure and wound care settings.
• Stratacel Flexible wound dressing specifically designed for repair of damaged or compromised skin following resurfacing procedures such as dermal abrasion, laser resurfacing, and chemical peels; suitable for sensitive areas including the periorbital area, lips, and nostrils. For aesthetic practitioners and patients undergoing skin rejuvenation procedures.
• Stratamark Novel medical product designed for the prevention and treatment of all types of stretch marks, particularly those covering wide surface areas resulting from pregnancy, adolescent growth spurts, weight gain/loss, or bodybuilding. Targeted at expectant mothers and individuals experiencing stretch marks.
• StrataXRT Innovative flexible wound dressing for the prevention and treatment of radiation dermatitis; film-forming gel that dries as a thin, flexible, and protective layer that is gas permeable and waterproof. Addresses skin reactions from erythema through moist desquamation. Indicated for oncology patients undergoing radiation therapy, chemotherapy, immunotherapy, or hematological treatments.
• StrataCTX Non-steroidal, semi-permeable, and self-drying gel for the management of dry skin and cutaneous rashes; can be applied directly to dry skin, open wounds, and compromised or desquamating skin surfaces, including cutaneous reactions from medications and inflammatory skin conditions. For oncology patients with treatment-related skin reactions and patients with inflammatory skin conditions.
• StrataMGT Innovative gel for vaginal atrophy and lichenoid dermatoses (sclerosus and planus); restores barrier function and moisture balance of the mucosal epidermis and relieves symptoms including itchiness, tenderness, dryness, burning sensation, dyspareunia, dysuria, and rectal pain. Suitable for short- and long-term use. For gynecologists and women with vaginal atrophy or lichenoid dermatoses.
• Colsigen Skincare product line powered by Humanized Type III Collagen to restore, renew, and rejuvenate compromised and injured skin following cosmetic procedures. For patients seeking post-procedure skin recovery and rejuvenation.

Quantifiable outcome

• StrataXRT reduces acute radiation dermatitis severity in breast cancer patients undergoing radiotherapy
• +3 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Research and Academic Institutions (Global Network)coreStrategic or Co-development PartnerStratpharma maintains a global investigation network through research agreements with prominent specialists, state-of-the-art universities, and promising start-ups. More than 20 collaborations with universities and research institutions. Collaborative innovation allows incorporation of external knowledge into R&D processes while accelerating development. A significant proportion of the pipeline is obtained through partnerships with universities, biotechnological and formulation companies globally.
• Distribution Partners (Pharmaceutical)coreChannel Partner/ Reseller/ DistributorStratpharma seeks distribution partners with well-established reputation in pharmaceutical distribution business. Partners should have well-developed relationships in pertinent distribution channels, with healthcare professionals and key opinion leaders. Focus on aesthetic medicine, dermatology, plastic surgery, wound care, women's health, and oncology. Company seeks best-in-class opportunities addressing unmet medical needs with potential to revolutionize standard of care.
• Clinical Trial Institutions (Various Countries)coreStrategic or Co-development PartnerStratpharma conducts clinical trials globally in partnership with institutions including: University of Geneva (Switzerland), Orange Coast Women's Medical Group (USA), Centers for Vulvovaginal Disorder New York (USA), and multiple sites across Europe, North America, South America, Asia, and Australasia for ongoing StrataXRT, StrataCTX, StrataMGT trials.

Scale indicators10 records

Recent moves12 records

Expansion highlights6 records

Emerging players

• Soligenix: Late-stage biopharmaceutical company named alongside Stratpharma in the radiation toxicity market, focused on proprietary photodynamic and therapeutic approaches for cutaneous radiation injury.
• KeraNetics: Named alongside Stratpharma in the radiation toxicity treatment market; an emerging player developing keratin-based treatments for wound and radiation indications, overlapping with StrataXRT clinically.

Broad incumbents

• Solventum: 3M's healthcare spin-off, Solventum is named alongside Stratpharma in the radiation toxicity treatment market and has a much larger wound care, dermatology, and surgical solutions portfolio competing broadly in the same end-markets.
• Mölnlycke Health Care: Global wound care and surgical solutions incumbent (Mepitel, Mepilex, Avance NPWT) that competes with Stratpharma across advanced wound dressings and post-procedure care categories in hospitals worldwide.
• Coloplast: Broad ostomy, wound, and skin care medical device company with overlapping wound and skin barrier product lines and similar specialty sales-channel model in oncology and dermatology settings.
• Smith & Nephew: Diversified global medical device player with sizable Advanced Wound Management franchise competing with Stratpharma in hospitals, burn care, and post-surgical wound care segments.
• ConvaTec: Established advanced wound care and ostomy medical device company with broad hospital and home-care distribution directly overlapping with Stratpharma's wound healing and skin integrity products.

Regional players

• Alliance Pharma: UK-based dermatology specialty pharma and medical device company with scar management (Kelocote) and women's health portfolio; competes in similar therapeutic areas through regional distribution channels.

Direct peers

• Biodermis: Specialty medical device company focused on silicone-based scar therapy (Pro-Sil, Silon technology) directly competing with Strataderm in the dermatologist- and consumer-recommended scar management category.
• Flen Health: Flen Health is explicitly named alongside Stratpharma as a key industry player in the global radiation toxicity treatment market, making it the most directly comparable peer in oncology supportive care and wound care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@stratpharmaswitzerland
• Facebookfacebook.com/stratpharmainc
• LinkedInlinkedin.com/company/stratpharma-ag
• Instagraminstagram.com/stratpharmausa

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stratpharma